Legend Biotech

Legend Biotech is an American clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. It is a subsidiary of Genscript Biotech Corporation. The company was founded in 2014 and is based in Somerset, New Jersey.
Legend Biotech stock price chart
+24%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Legend Biotech balance sheet

Report period2018 2019 2020 2021 2022Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Legend Biotech cash flows

Report period2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Legend Biotech multipliers

Report period2018 2019 2020 2021 2022Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Legend Biotech profitability

Report period2018 2019 2020 2021 2022Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Legend Biotech assets
Legend Biotech cash flows

Legend Biotech dividend policy

The company doesn't provide dividend

Legend Biotech shares

TickerNameTypeNominal valueISINPrice
LEGN:USLegend BiotechCommon share-US52490G1022$58.14
Legend Biotech news
01.06.2022
Legend Biotech's GAAP loss for 3 months of 2022 was $41.087 million, down 49.2% from $80.899 million in the previous year. Revenue tripled to $40.827 million from $13.682 million a year earlier.
26.05.2022
European Commission has granted conditional approval for CARVYKTI by Legend Biotech. The drug is intended to treat adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and have demonstrated disease progression on the last therapy. The drug was approved by the FDA in February of this year.
21.03.2022
Legend Biotech's GAAP loss for 2021 was $386.209 million, up 27.3% from $303.477 million in the previous year. Revenue increased 18.7% to $89.792 million from $75.676 million a year earlier.
16.11.2021
Legend Biotech's GAAP loss for 9M 2021 was $297.875 million, up 21.3% from $245.65 million in the prior year. Revenue increased 45.6% to $50.797 million from $34.893 million a year earlier.
General information
Company nameLegend Biotech
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address2101 Cottontail Lane Somerset, NJ 08873 United States
Mailing address2101 Cottontail Lane Somerset, NJ 08873 United States
Websiteinvestors.legendbiotech.com
Information disclosurewww.sec.gov